Drug-eluting stents

Area of Science:

• Cardiovascular Medicine
• Biomaterials Science
• Interventional Cardiology

Background:

• Coronary artery disease (CAD) remains a primary global cause of mortality.
• Drug-eluting stents (DESs) are crucial in interventional cardiology for reducing restenosis.
• Late-stage stent thrombosis is a significant adverse event associated with DES.

Purpose of the Study:

• To review the developmental progress of the three core components of DES.
• To elucidate the impact of each DES component on restenosis and thrombosis.
• To offer insights for the future design of improved DES.

Main Methods:

• Comprehensive literature review focusing on stent platforms, drug delivery vehicles, and therapeutic agents used in DES.
• Analysis of studies evaluating the efficacy and safety profiles of various DES components.
• Synthesis of data on the mechanisms underlying restenosis and thrombosis related to DES.

Main Results:

• The stent platform influences biocompatibility and thrombogenicity.
• Drug delivery vehicles modulate drug release kinetics, affecting both efficacy and safety.
• The choice of drug and its elution profile are critical for preventing neointimal hyperplasia and thrombosis.

Conclusions:

• Optimizing stent platform, drug carrier, and drug selection is essential for next-generation DES.
• Future DES designs should aim to balance anti-restenotic effects with minimized thrombotic risk.
• Further research into component interactions will enhance DES performance in treating CAD.